Genzyme Pharmaceuticals, a division of leading biotech firm Genzyme, couldn't agree more. The division, at its main production facility in Liestal, Switzerland, makes chemical intermediates and active pharmaceutical ingredients used in the production of a number of drugs, many manufactured by its parent. Its main products include natural and synthetic lipids and amino acid derivatives. It has also partnered with major pharmaceutical companies to develop custom manufacturing of drugs currently in development. Additionally, Genzyme Pharmaceuticals manufactures lipid-based drug delivery systems.

MPI Research was founded in 1962. MPI Research helps drug developers answer a crucial question: Is it safe? The contract research organization (CRO) specializes in providing pre-clinical research services to pharmaceutical, medical device, chemical, and agricultural development companies, as well as regulatory and other government agencies. Its toxicology testing services investigate and determine the safety and dosage levels of substances being considered for use in drugs, pesticides, petrochemicals, and food additives. MPI Research also offers contract bioanalytical and pharmacology services.

SciClone Pharmaceuticals, Inc. company was founded in 1989 and is headquartered in Foster City, California. SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally. It provides ZADAXIN for the treatment of hepatitis B and hepatitis C, and certain cancers, as well as for use as a vaccine adjuvant. SciClone's products under development includes ZADAXIN, a thymalfasin, which is in Phase III clinical trials for the treatment of stage IV melanoma; RP101, which is in Phase II clinical trials for the treatment of pancreatic cancer; and SCV-07, which is in Phase II clinical trials for the treatment of hepatitis C virus and oral mucositis. It also holds Chinese marketing rights from Biocompatibles International plc. for DC Bead, a product for the treatment of liver cancer or hepatocellular carcinoma.

CGI Pharmaceuticals (formerly Cellular Genomics) is using a chemical genetics platform to discover and develop new therapies for cancer and inflammatory diseases. The company also helps other drug makers fill their pipelines with the help of its chemical genetics screening technology. Its specialty is identifying and developing kinase inhibitor therapeutics, but it also offers assay development, in vivo disease modeling, and clinical and regulatory affairs management. Partners include Pfizer, Merck Serono, and Eli Lilly.

Phytopharm is hunting for better drugs. The company struck a deal with Unilever in late 2004 to develop a slimming aid based on the African cactus hoodia, used in Africa to stave off hunger during hunting trips. This developer of botanical pharmaceuticals concentrates on four drug-discovery areas -- obesity and metabolic disease, neurodegeneration, inflammation, and dermatology. In addition, Phytopharm markets two veterinary dermatology products in the UK.

Trubion Pharmaceuticals, Inc.company was founded in 1999 and is headquartered in Seattle, Washington. Trubion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases and cancer. The company, in a collaboration with Wyeth, is conducting a phase IIb clinical trial for its lead product candidate, TRU-015, for the treatment of rheumatoid arthritis. The company also offers TRU-016, a phase II/II clinical evaluation product and a novel CD37-targeted therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and certain autoimmune and inflammatory disease indications. It also has collaboration agreement with Wyeth for the development and commercialization of SBI-087 for the treatment of rheumatoid arthritis and SBI-087 for the treatment of systemic lupus erythematosus, as well as other therapeutics directed to CD20, an antigen that is a validated clinical target present on B cells.

Alexion Pharmaceuticals was founded in 1992 and is headquartered in Cheshire, Connecticut. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and delivers drug therapies for patients with various medical conditions. It primarily engages in the discovery, development, and commercialization of biologic therapeutic products for the treatment of various disease states, including hematologic and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. The company primarily markets Soliris (eculizumab) in the United States and Europe for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder. It is also evaluating other indications for Soliris, as well as other formulations of eculizumab for additional clinical indications. In addition, the company is developing Anti-CD200 antibody for the treatment of B-Cell Chronic Lymphocytic Leukemia, a cancer that results from expansion of B-lymphocytes and other cancers.Alexion Pharmaceuticals drug programs include Eculizumab (intravenous), a phase II product candidate for atypical HUS, presensitized renal transplant, myasthenia gravis, multifocal motor neuropathy, dense deposit disease, catastrophic antiphospholipid syndrome, and cold agglutinin disease; CD200 Mab, which is in phase I/II clinical trial for the treatment of chronic lymphocytic leukemia and in preclinical stage for the treatment of multiple myeloma; and Eculizumab (new formulation) that is under phase I/II clinical trial for the treatment of asthma. Its customers include specialty distributors and specialty pharmacies who supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, and other health care providers and distributors.

Formerly known as Stone Electronic Technology Limited, Stone Group Holdings Limited (Stock code: 409) was established on September 3, 1987. After a successful restructuring exercise in 1993, the Company became the first non-state-owned share-holding company in the PRC listed on the Stock Exchange of Hong Kong in August 1993. It is principally engaged in IT electronic & media – related business in mainland China, healthcare products business and investment business.The Company's IT electronic and media-related business includes the manufacture and distribution of traditional electronic products and the operation of internet café chain. Electronic products include dot matrix printer and value-added tax control machine with patented intellectual property, and the Group also acts as the agent and distributor of industrial controllers, uninterrupted power system equipment, digital graphics, semiconductors, computers etc.. Product coverage includes SIEMENS, FUJI. The internet café chain – Sunnet café is located in Guangdong Province.

Alacer Corp. will "C" you through your cold. Maker of the popular Emergen-C fizzy drink mix, the company set the cornerstone on branded vitamin C products. In addition to Emergen-C, which blends mineral ascorbates with B vitamins and mineral complexes, the company's other products include ElectroMIX (electrolyte drink mix) and its Super Gram time-released tablets. Alacer also develops other vitamin and herbal supplements, all with a walloping dose of vitamin C stirred in. Its products are sold through natural foods retailers, mass market retailers, and chain drug stores.

Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States. The company's lead product candidate includes RDEA594, a product for the treatment of hyperuricemia and gout. Its other products comprise RDEA806 for the treatment of patients with HIV; and RDEA427, a second-generation NNRTI for the treatment of HIV, in a human micro-dose pharmacokinetic study. Ardea Biosciences is evaluating RDEA119, a non-ATP EK inhibitor, in a Phase I/II study in combination with sorafenib and as a single agent in a Phase I study, both in advanced cancer patients. It also develops RDEA436 for the treatment of inflammation. The company is based in San Diego, California.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.